93,521 Shares of Collegium Pharmaceutical, Inc. $COLL Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 93,521 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,041,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in COLL. BlackRock Inc. acquired a new stake in shares of Collegium Pharmaceutical during the 2nd quarter worth approximately $196,972,000. Jupiter Topco LLC bought a new position in Collegium Pharmaceutical in the second quarter valued at approximately $77,743,000. Janus Henderson Group PLC increased its stake in Collegium Pharmaceutical by 26.0% in the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after acquiring an additional 377,073 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Collegium Pharmaceutical by 0.3% in the first quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company’s stock valued at $27,551,000 after acquiring an additional 2,712 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in Collegium Pharmaceutical by 29.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company’s stock valued at $23,266,000 after purchasing an additional 159,755 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised Collegium Pharmaceutical from a “strong sell” rating to a “strong-buy” rating in a report on Thursday, October 15th. Weiss Ratings downgraded Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Oppenheimer assumed coverage on Collegium Pharmaceutical in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Leerink Partners assumed coverage on Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $48.71.

Collegium Pharmaceutical Trading Up 1.0%

Shares of Collegium Pharmaceutical stock opened at $23.23 on Thursday. The firm has a market capitalization of $756.37 million, a PE ratio of 18.73, a price-to-earnings-growth ratio of 0.71 and a beta of 0.73. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The firm’s 50 day moving average is $23.47 and its 200 day moving average is $33.59. Collegium Pharmaceutical, Inc. has a 1 year low of $21.43 and a 1 year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.68 EPS. Equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.42 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.